Cite
HARVARD Citation
Keech, C. et al. (2023). Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Lancet. 401 (10379), pp. 843-855. [Online].